Review

Pharmacogenomics of lipid-lowering therapies

Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR

Search for more papers by this author

Brian Tomlinson

* Author for correspondence

Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR. .

Search for more papers by this author

Email the corresponding author at btomlinson@cuhk.edu.hk

Published Online:7 Jun 2013https://doi.org/10.2217/pgs.13.71

View article

Abstract

Statins are the most widely used group of lipid-lowering drugs and they have been shown to be effective in the prevention of cardiovascular disease, primarily by reducing plasma low-density lipoprotein cholesterol concentrations and possibly through other pleiotropic effects. However, there are large variations in lipid responses to statins and some patients have intolerable muscle adverse drug reactions, which may in part be related to genetic factors. In the last decade, pharmacogenetic studies on statins ranging from the candidate gene approach to the more recent genome-wide association studies have provided evidence that genetic variations play an important role in determining statin responses. This review summarizes the current understanding on the pharmacogenomics of statins and other lipid-lowering drugs in current use.

Keywords:

Papers of special note have been highlighted as: ▪ of interest

References

1 Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target: a systematic review. JAMA298(7),786–798 (2007).Crossref, Medline, CAS, Google Scholar
2 Sarwar N, Sandhu MS, Ricketts SL et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet375(9726),1634–1639 (2010).Crossref, Medline, CAS, Google Scholar
3 Nordestgaard BG, Chapman MJ, Ray K et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur. Heart J.31(23),2844–2853 (2010).Crossref, Medline, CAS, Google Scholar
4 Voight BF, Peloso GM, Orho-Melander M et al. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet380(9841),572–580 (2012).Crossref, Medline, CAS, Google Scholar
5 Baigent C, Blackwell L, Emberson J et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet376(9753),1670–1681 (2010).Crossref, Medline, CAS, Google Scholar
6 Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet366(9493),1267–1278 (2005).Crossref, Medline, CAS, Google Scholar
7 Mihaylova B, Emberson J, Blackwell L et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet380(9841),581–590 (2012).Crossref, Medline, CAS, Google Scholar
8 Mihos CG, Salas MJ, Santana O. The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in cardiovascular disease: a comprehensive review. Cardiol. Rev.18(6),298–304 (2010).Crossref, Medline, Google Scholar
9 Hu M, Mak VWL, Chu TTY, Waye MMY, Tomlinson B. Pharmacogenetics of HMG-CoA reductase inhibitors: optimizing the prevention of coronary heart disease. Curr. Pharmacogenomics Pers. Med.7(1),1–26 (2009).Crossref, Google Scholar
10 Sirtori CR, Mombelli G, Triolo M, Laaksonen R. Clinical response to statins: mechanism(s) of variable activity and adverse effects. Ann. Med.44(5),419–432 (2012).Crossref, Medline, CAS, Google Scholar
11 Postmus I, Verschuren JJ, De Craen AJ et al. Pharmacogenetics of statins: achievements, whole-genome analyses and future perspectives. Pharmacogenomics13(7),831–840 (2012).▪ Recent review of the pharmacogenetics of statins.Link, CAS, Google Scholar
12 Mangravite LM, Thorn CF, Krauss RM. Clinical implications of pharmacogenomics of statin treatment. Pharmacogenomics J.6(6),360–374 (2006).Crossref, Medline, CAS, Google Scholar
13 Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin. Pharmacol. Ther.80(6),565–581 (2006).Crossref, Medline, CAS, Google Scholar
14 Neuvonen PJ, Backman JT, Niemi M. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. Clin. Pharmacokinet.47(7),463–474 (2008).Crossref, Medline, CAS, Google Scholar
15 Elsby R, Hilgendorf C, Fenner K. Understanding the critical disposition pathways of statins to assess drug–drug interaction risk during drug development: it’s not just about OATP1B1. Clin. Pharmacol. Ther.92(5),584–598 (2012).Crossref, Medline, CAS, Google Scholar
16 Hu M, Mak VW, Xiao Y, Tomlinson B. Associations between the genotypes and phenotype of CYP3A and the lipid response to simvastatin in Chinese patients with hypercholesterolemia. Pharmacogenomics14(1),25–34 (2013).Link, CAS, Google Scholar
17 Wang D, Guo Y, Wrighton SA, Cooke GE, Sadee W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J.11(4),274–286 (2011).Crossref, Medline, Google Scholar
18 Elens L, Becker ML, Haufroid V et al. Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study. Pharmacogenet. Genomics21(12),861–866 (2011).Crossref, Medline, CAS, Google Scholar
19 Romaine SP, Bailey KM, Hall AS, Balmforth AJ. The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. Pharmacogenomics J.10(1),1–11 (2010).Crossref, Medline, CAS, Google Scholar
20 Hu M, To KK, Mak VW, Tomlinson B. The ABCG2 transporter and its relations with the pharmacokinetics, drug interaction and lipid-lowering effects of statins. Expert Opin. Drug Metab. Toxicol.7(1),49–62 (2011).Crossref, Medline, CAS, Google Scholar
21 Rodrigues AC. Efflux and uptake transporters as determinants of statin response. Expert Opin. Drug Metab. Toxicol.6(5),621–632 (2010).Crossref, Medline, CAS, Google Scholar
22 Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol. Rev.63(1),157–181 (2011).Crossref, Medline, CAS, Google Scholar
23 Nezasa K, Higaki K, Matsumura T et al. Liver-specific distribution of rosuvastatin in rats: comparison with pravastatin and simvastatin. Drug Metab. Dispos.30(11),1158–1163 (2002).Crossref, Medline, CAS, Google Scholar
24 Niemi M. Transporter pharmacogenetics and statin toxicity. Clin. Pharmacol. Ther.87(1),130–133 (2010).▪ Summary of the pharmacogenetic studies on variants in transporters and statin toxicity.Crossref, Medline, CAS, Google Scholar
25 Link E, Parish S, Armitage J et al. SLCO1B1 variants and statin-induced myopathy – a genomewide study. N. Engl. J. Med.359(8),789–799 (2008).▪ First genome-wide analysis of high-dose simvastatin-induced myopathy.Crossref, Medline, CAS, Google Scholar
26 Donnelly LA, Doney AS, Tavendale R et al. Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with Type 2 diabetes: a go-DARTS study. Clin. Pharmacol. Ther.89(2),210–216 (2011).Crossref, Medline, CAS, Google Scholar
27 Voora D, Shah SH, Spasojevic I et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J. Am. Coll. Cardiol.54(17),1609–1616 (2009).Crossref, Medline, CAS, Google Scholar
28 Elhayany A, Mishaal RA, Vinker S. Is there clinical benefit to routine enzyme testing of patients on statins? Expert Opin. Drug Saf.11(2),185–190 (2012).Crossref, Medline, CAS, Google Scholar
29 Brunham LR, Lansberg PJ, Zhang L et al. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J.12(3),233–237 (2012).Crossref, Medline, CAS, Google Scholar
30 Santos PC, Gagliardi AC, Miname MH et al.SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia. Eur. J. Clin. Pharmacol.68(3),273–279 (2012).Crossref, Medline, CAS, Google Scholar
31 Keskitalo JE, Pasanen MK, Neuvonen PJ, Niemi M. Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. Pharmacogenomics10(10),1617–1624 (2009).Link, CAS, Google Scholar
32 Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, Niemi M. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin. Pharmacol. Ther.86(2),197–203 (2009).Crossref, Medline, CAS, Google Scholar
33 Hu M, Lui SS, Mak VW et al. Pharmacogenetic analysis of lipid responses to rosuvastatin in Chinese patients. Pharmacogenet. Genomics20(10),634–637 (2010).Crossref, Medline, CAS, Google Scholar
34 Tomlinson B, Hu M, Lee VW et al.ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin. Clin. Pharmacol. Ther.87(5),558–562 (2010).Crossref, Medline, CAS, Google Scholar
35 Bailey KM, Romaine SP, Jackson BM et al. Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study. Circ. Cardiovasc. Genet.3(3),276–285 (2010).Crossref, Medline, CAS, Google Scholar
36 Zhang W, Yu BN, He YJ et al. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin. Chim. Acta373(1–2),99–103 (2006).Crossref, Medline, CAS, Google Scholar
37 Chasman DI, Posada D, Subrahmanyan L, Cook NR, Stanton VP Jr, Ridker PM. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA291(23),2821–2827 (2004).Crossref, Medline, CAS, Google Scholar
38 Krauss RM, Mangravite LM, Smith JD et al. Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment. Circulation117(12),1537–1544 (2008).Crossref, Medline, CAS, Google Scholar
39 Thompson JF, Hyde CL, Wood LS et al. Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the Treating to New Targets (TNT) cohort. Circ. Cardiovasc. Genet.2(2),173–181 (2009).▪ First genome-wide analysis of lipid responses to atorvastatin in the TNT cohort.Crossref, Medline, CAS, Google Scholar
40 Singer JB, Holdaas H, Jardine AG et al. Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients. J. Lipid Res.48(9),2072–2078 (2007).Crossref, Medline, CAS, Google Scholar
41 Polisecki E, Muallem H, Maeda N et al. Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER. Atherosclerosis200(1),109–114 (2008).Crossref, Medline, CAS, Google Scholar
42 Yamamoto A, Kamiya T, Yamamura T et al. Clinical features of familial hypercholesterolemia. Arteriosclerosis9(Suppl. 1),I66–I74 (1989).Medline, CAS, Google Scholar
43 Couture P, Brun LD, Szots F et al. Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadians with heterozygous familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol.18(6),1007–1012 (1998).Crossref, Medline, CAS, Google Scholar
44 Miltiadous G, Xenophontos S, Bairaktari E, Ganotakis M, Cariolou M, Elisaf M. Genetic and environmental factors affecting the response to statin therapy in patients with molecularly defined familial hypercholesterolaemia. Pharmacogenet. Genomics15(4),219–225 (2005).Crossref, Medline, CAS, Google Scholar
45 Kajinami K, Yagi K, Higashikata T, Inazu A, Koizumi J, Mabuchi H. Low-density lipoprotein receptor genotype-dependent response to cholesterol lowering by combined pravastatin and cholestyramine in familial hypercholesterolemia. Am. J. Cardiol.82(1),113–117 (1998).Crossref, Medline, CAS, Google Scholar
46 Thompson JF, Man M, Johnson KJ et al. An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J.5(6),352–358 (2005).Crossref, Medline, CAS, Google Scholar
47 Mousavi SA, Berge KE, Leren TP. The unique role of proprotein convertase subtilisin/kexin 9 in cholesterol homeostasis. J. Intern. Med.266(6),507–519 (2009).Crossref, Medline, CAS, Google Scholar
48 Abifadel M, Rabes JP, Devillers M et al. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. Hum. Mutat.30(4),520–529 (2009).Crossref, Medline, CAS, Google Scholar
49 Soutar AK, Naoumova RP. Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat. Clin. Pract. Cardiovasc. Med.4(4),214–225 (2007).Crossref, Medline, CAS, Google Scholar
50 Konrad RJ, Troutt JS, Cao G. Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents. Lipids Health Dis.10,38 (2011).Crossref, Medline, CAS, Google Scholar
51 Naoumova RP, Tosi I, Patel D et al. Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response. Arterioscler. Thromb. Vasc. Biol.25(12),2654–2660 (2005).Crossref, Medline, CAS, Google Scholar
52 Pisciotta L, Sallo R, Rabacchi C, Wunsch A, Calandra S, Bertolini S. Leucine 10 allelic variant in signal peptide of PCSK9 increases the LDL cholesterol-lowering effect of statins in patients with familial hypercholesterolaemia. Nutr. Metab. Cardiovasc. Dis.22(10),831–835 (2012).Crossref, Medline, CAS, Google Scholar
53 Chen SN, Ballantyne CM, Gotto AM Jr, Tan Y, Willerson JT, Marian AJ. A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. J. Am. Coll. Cardiol.45(10),1611–1619 (2005).Crossref, Medline, CAS, Google Scholar
54 Norata GD, Garlaschelli K, Grigore L et al. Effects of PCSK9 variants on common carotid artery intima media thickness and relation to ApoE alleles. Atherosclerosis208(1),177–182 (2010).Crossref, Medline, CAS, Google Scholar
55 Kotowski IK, Pertsemlidis A, Luke A et al. A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am. J. Hum. Genet.78(3),410–422 (2006).Crossref, Medline, CAS, Google Scholar
56 Peters BJ, Pett H, Klungel OH et al. Genetic variability within the cholesterol lowering pathway and the effectiveness of statins in reducing the risk of MI. Atherosclerosis217(2),458–464 (2011).Crossref, Medline, CAS, Google Scholar
57 Nieminen T, Kahonen M, Viiri LE, Gronroos P, Lehtimaki T. Pharmacogenetics of apolipoprotein E gene during lipid-lowering therapy: lipid levels and prevention of coronary heart disease. Pharmacogenomics9(10),1475–1486 (2008).Link, CAS, Google Scholar
58 Voora D, Shah SH, Reed CR et al. Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response. Circ. Cardiovasc. Genet.1(2),100–106 (2008).Crossref, Medline, CAS, Google Scholar
59 Mega JL, Morrow DA, Brown A, Cannon CP, Sabatine MS. Identification of genetic variants associated with response to statin therapy. Arterioscler. Thromb. Vasc. Biol.29(9),1310–1315 (2009).Crossref, Medline, CAS, Google Scholar
60 Gerdes LU, Gerdes C, Kervinen K et al. The apolipoprotein ε4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: a substudy of the Scandinavian simvastatin survival study. Circulation101(12),1366–1371 (2000).Crossref, Medline, CAS, Google Scholar
61 Chiodini BD, Franzosi MG, Barlera S et al. Apolipoprotein E polymorphisms influence effect of pravastatin on survival after myocardial infarction in a Mediterranean population: the GISSI-Prevenzione study. Eur. Heart J.28(16),1977–1983 (2007).Crossref, Medline, CAS, Google Scholar
62 Schnapp BJ. Trafficking of signaling modules by kinesin motors. J. Cell Sci.116(Pt 11),2125–2135 (2003).Crossref, Medline, CAS, Google Scholar
63 Morrison AC, Bare LA, Chambless LE et al. Prediction of coronary heart disease risk using a genetic risk score: the atherosclerosis risk in communities study. Am. J. Epidemiol.166(1),28–35 (2007).Crossref, Medline, Google Scholar
64 Shiffman D, Chasman DI, Zee RY et al. A kinesin family member 6 variant is associated with coronary heart disease in the Women’s Health Study. J. Am. Coll. Cardiol.51(4),444–448 (2008).Crossref, Medline, CAS, Google Scholar
65 Iakoubova OA, Sabatine MS, Rowland CM et al. Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study. J. Am. Coll. Cardiol.51(4),449–455 (2008).Crossref, Medline, CAS, Google Scholar
66 Iakoubova OA, Tong CH, Rowland CM et al. Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. J. Am. Coll. Cardiol.51(4),435–443 (2008).Crossref, Medline, CAS, Google Scholar
67 Assimes TL, Holm H, Kathiresan S et al. Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and coronary artery disease in 19 case–control studies. J. Am. Coll. Cardiol.56(19),1552–1563 (2010).Crossref, Medline, CAS, Google Scholar
68 Hoffmann MM, Marz W, Genser B, Drechsler C, Wanner C. Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and cardiovascular risk and efficacy of atorvastatin among subjects with diabetes on dialysis: the 4D study. Atherosclerosis219(2),659–662 (2011).Crossref, Medline, CAS, Google Scholar
69 Ridker PM, MacFadyen JG, Glynn RJ, Chasman DI. Kinesin-like protein 6 (KIF6) polymorphism and the efficacy of rosuvastatin in primary prevention. Circ. Cardiovasc. Genet.4(3),312–317 (2011).Crossref, Medline, CAS, Google Scholar
70 Hopewell JC, Parish S, Clarke R et al. No impact of KIF6 genotype on vascular risk and statin response among 18,348 randomized patients in the heart protection study. J. Am. Coll. Cardiol.57(20),2000–2007 (2011).Crossref, Medline, CAS, Google Scholar
71 Arsenault BJ, Boekholdt SM, Hovingh GK et al. The 719Arg variant of KIF6 and cardiovascular outcomes in statin-treated, stable coronary patients of the treating to new targets and incremental decrease in end points through aggressive lipid-lowering prospective studies. Circ. Cardiovasc. Genet.5(1),51–57 (2012).Crossref, Medline, CAS, Google Scholar
72 Marciante KD, Durda JP, Heckbert SR et al. Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet. Genomics21(5),280–288 (2011).Crossref, Medline, CAS, Google Scholar
73 Isackson PJ, Ochs-Balcom HM, Ma C et al. Association of common variants in the human eyes shut ortholog (EYS) with statin-induced myopathy: evidence for additional functions of EYS. Muscle Nerve44(4),531–538 (2011).Crossref, Medline, CAS, Google Scholar
74 Chasman DI, Giulianini F, MacFadyen J, Barratt BJ, Nyberg F, Ridker PM. Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. Circ. Cardiovasc. Genet.5(2),257–264 (2012).▪ Genome-wide analysis of the lipid responses to rosuvastatin in a large randomized trial.Crossref, Medline, CAS, Google Scholar
75 Deshmukh HA, Colhoun HM, Johnson T et al. Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a). J. Lipid Res.53(5),1000–1011 (2012).▪ Genome-wide analysis of lipid responses to atorvastatin in Caucasians.Crossref, Medline, CAS, Google Scholar
76 Hopewell JC, Parish S, Offer A et al. Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study. Eur. Heart J.34(13),982–992 (2012).▪ Genome-wide analysis of lipid responses to simvastatin in the HPS.Crossref, Medline, Google Scholar
77 Barber MJ, Mangravite LM, Hyde CL et al. Genome-wide association of lipid-lowering response to statins in combined study populations. PLoS ONE5(3),e9763 (2010).Crossref, Medline, Google Scholar
78 Chu AY, Guilianini F, Barratt BJ, Nyberg F, Chasman DI, Ridker PM. Pharmacogenetic determinants of statin-induced reductions in C-reactive protein. Circ. Cardiovasc. Genet.5(1),58–65 (2012).Crossref, Medline, CAS, Google Scholar
79 Thompson A, Gao P, Orfei L et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet375(9725),1536–1544 (2010).Crossref, Medline, CAS, Google Scholar
80 Chu AY, Guilianini F, Grallert H et al. Genome-wide association study evaluating lipoprotein-associated phospholipase A2 mass and activity at baseline and after rosuvastatin therapy. Circ. Cardiovasc. Genet.5(6),676–685 (2012).Crossref, Medline, CAS, Google Scholar
81 Shiffman D, Trompet S, Louie JZ et al. Genome-wide study of gene variants associated with differential cardiovascular event reduction by pravastatin therapy. PLoS ONE7(5),e38240 (2012).Crossref, Medline, CAS, Google Scholar
82 Phan BA, Dayspring TD, Toth PP. Ezetimibe therapy: mechanism of action and clinical update. Vasc. Health Risk Manag.8,415–427 (2012).Medline, CAS, Google Scholar
83 Leiter LA, Betteridge DJ, Farnier M et al. Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials. Diabetes Obes. Metab.13(7),615–628 (2011).Crossref, Medline, CAS, Google Scholar
84 Lioudaki E, Ganotakis ES, Mikhailidis DP. Ezetimibe; more than a low density lipoprotein cholesterol lowering drug? an update after 4 years. Curr. Vasc. Pharmacol.9(1),62–86 (2011).Crossref, Medline, CAS, Google Scholar
85 Pisciotta L, Fasano T, Bellocchio A et al. Effect of ezetimibe coadministered with statins in genotype-confirmed heterozygous FH patients. Atherosclerosis194(2),e116–e122 (2007).Crossref, Medline, CAS, Google Scholar
86 Hegele RA, Guy J, Ban MR, Wang J. NPC1L1 haplotype is associated with inter-individual variation in plasma low-density lipoprotein response to ezetimibe. Lipids Health Dis.4,16 (2005).Crossref, Medline, Google Scholar
87 Simon JS, Karnoub MC, Devlin DJ et al. Sequence variation in NPC1L1 and association with improved LDL-cholesterol lowering in response to ezetimibe treatment. Genomics86(6),648–656 (2005).Crossref, Medline, CAS, Google Scholar
88 Berthold HK, Laaksonen R, Lehtimaki T, Gylling H, Krone W, Gouni-Berthold I. SREBP-1c gene polymorphism is associated with increased inhibition of cholesterol-absorption in response to ezetimibe treatment. Exp. Clin. Endocrinol. Diabetes116(5),262–267 (2008).Crossref, Medline, CAS, Google Scholar
89 Chapman MJ, Redfern JS, McGovern ME, Giral P. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol. Ther.126(3),314–345 (2010).Crossref, Medline, CAS, Google Scholar
90 Perez-Martinez P, Corella D, Shen J et al. Association between glucokinase regulatory protein (GCKR) and apolipoprotein A5 (APOA5) gene polymorphisms and triacylglycerol concentrations in fasting, postprandial, and fenofibrate-treated states. Am. J. Clin. Nutr.89(1),391–399 (2009).Crossref, Medline, CAS, Google Scholar
91 Cardona F, Guardiola M, Queipo-Ortuno MI, Murri M, Ribalta J, Tinahones FJ. The -1131T>C SNP of the APOA5 gene modulates response to fenofibrate treatment in patients with the metabolic syndrome: a postprandial study. Atherosclerosis206(1),148–152 (2009).Crossref, Medline, CAS, Google Scholar
92 Lai CQ, Arnett DK, Corella D et al. Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study. Arterioscler. Thromb. Vasc. Biol.27(6),1417–1425 (2007).Crossref, Medline, CAS, Google Scholar
93 Smith JA, Arnett DK, Kelly RJ et al. The genetic architecture of fasting plasma triglyceride response to fenofibrate treatment. Eur. J. Hum. Genet.16(5),603–613 (2008).Crossref, Medline, CAS, Google Scholar
94 Boden WE, Probstfield JL, Anderson T et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med.365(24),2255–2267 (2011).Crossref, Medline, Google Scholar
95 Hu M, Chu WC, Yamashita S et al. Liver fat reduction with niacin is influenced by DGAT-2 polymorphisms in hypertriglyceridemic patients. J. Lipid Res.53(4),802–809 (2012).Crossref, Medline, CAS, Google Scholar
96 Brautbar A, Covarrubias D, Belmont J et al. Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. Atherosclerosis219(2),737–742 (2011).Crossref, Medline, CAS, Google Scholar
97 Brautbar A, Virani SS, Belmont J, Nambi V, Jones PH, Ballantyne CM. LPL gene variants affect apoC-III response to combination therapy of statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. J. Lipid Res.53(3),556–560 (2012).Crossref, Medline, CAS, Google Scholar
98 Wilke RA, Ramsey LB, Johnson SG et al. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin. Pharmacol. Ther.92(1),112–117 (2012).Crossref, Medline, CAS, Google Scholar
99 Cordero P, Ashley EA. Whole-genome sequencing in personalized therapeutics. Clin. Pharmacol. Ther.91(6),1001–1009 (2012).Crossref, Medline, CAS, Google Scholar
100 Liu Y, Ordovas JM, Gao G et al. Pharmacogenetic association of the APOA1/C3/A4/A5 gene cluster and lipid responses to fenofibrate: the genetics of lipid-lowering drugs and diet network study. Pharmacogenet. Genomics19(2),161–169 (2009).Crossref, Medline, CAS, Google Scholar
101 Wojczynski MK, Gao G, Borecki I et al. Apolipoprotein B genetic variants modify the response to fenofibrate: a GOLDN study. J. Lipid Res.51(11),3316–3323 (2010).Crossref, Medline, CAS, Google Scholar
102 Irvin MR, Kabagambe EK, Tiwari HK et al. Apolipoprotein E polymorphisms and postprandial triglyceridemia before and after fenofibrate treatment in the Genetics of Lipid Lowering and Diet Network (GOLDN) Study. Circ. Cardiovasc. Genet.3(5),462–467 (2010).Crossref, Medline, CAS, Google Scholar
103 Christidis DS, Liberopoulos EN, Kakafika AI et al. The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate. J. Cardiovasc. Pharmacol. Ther.11(3),211–221 (2006).Crossref, Medline, CAS, Google Scholar
104 Brisson D, Ledoux K, Bosse Y et al. Effect of apolipoprotein E, peroxisome proliferator-activated receptor α and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients. Pharmacogenetics12(4),313–320 (2002).Crossref, Medline, CAS, Google Scholar
105 Shen J, Arnett DK, Parnell LD et al. The effect of CYP7A1 polymorphisms on lipid responses to fenofibrate. J. Cardiovasc. Pharmacol.59(3),254–259 (2012).Crossref, Medline, CAS, Google Scholar
106 Brouillette C, Bosse Y, Perusse L, Gaudet D, Vohl MC. Effect of liver fatty acid binding protein (FABP) T94A missense mutation on plasma lipoprotein responsiveness to treatment with fenofibrate. J. Hum. Genet.49(8),424–432 (2004).Crossref, Medline, CAS, Google Scholar
107 Chien KL, Lin YL, Wen HC et al. Common sequence variant in lipoprotein lipase gene conferring triglyceride response to fibrate treatment. Pharmacogenomics10(2),267–276 (2009).Link, CAS, Google Scholar
108 Liu Y, Ordovas JM, Gao G et al. The SCARB1 gene is associated with lipid response to dietary and pharmacological interventions. J. Hum. Genet.53(8),709–717 (2008).Crossref, Medline, Google Scholar
109 Foucher C, Rattier S, Flavell DM et al. Response to micronized fenofibrate treatment is associated with the peroxisome-proliferator-activated receptors α G/C intron7 polymorphism in subjects with Type 2 diabetes. Pharmacogenetics14(12),823–829 (2004).Crossref, Medline, CAS, Google Scholar
110 Shen J, Arnett DK, Parnell LD et al. Association of common C-reactive protein (CRP) gene polymorphisms with baseline plasma CRP levels and fenofibrate response: the GOLDN study. Diabetes Care31(5),910–915 (2008).Crossref, Medline, CAS, Google Scholar
111 Aslibekyan S, Kabagambe EK, Irvin MR et al. A genome-wide association study of inflammatory biomarker changes in response to fenofibrate treatment in the genetics of lipid lowering drug and diet network. Pharmacogenet. Genomics22(3),191–197 (2012).Crossref, Medline, CAS, Google Scholar

Vol. 14, No. 8

Metrics

Downloaded 395 times

History

Published online 7 June 2013

Published in print June 2013

Information

Keywords

Disclaimer

This work is that of the authors and does not represent the opinions of the mentioned funding bodies.

Financial & competing interests disclosure

B Tomlinson has received research funding to perform clinical studies from Abbott Laboratories Ltd, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck Serono, Merck Sharp and Dohme, Novartis, Roche and Takeda, and has acted as a consultant or speaker on occasions for Amgen, AstraZeneca, Boehringer Ingelheim, Genzyme, Janssen, Merck Serono, Merck Sharp and Dohme, Ranbaxy and Servier. The work described in this paper was partly supported by grants from the Research Grants Council (Project no. CUHK 4472/06M) and the Food and Health Bureau (Project no. HHSRF 09100321) of the Hong Kong Special Administrative Region, China. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

PDF download